Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of treatment for head and neck cancer

Bruce E Brockstein, MD
Kerstin M Stenson, MD, FACS
Shiyu Song, MD, PhD
Section Editors
Marshall R Posner, MD
Marvin P Fried, MD, FACS
David M Brizel, MD
Deputy Editor
Michael E Ross, MD


Most head and neck cancers begin in the mucosal surfaces of the upper aerodigestive tract, and these are predominantly squamous cell carcinomas.

An overview of treatment for head and neck squamous cell carcinomas will be presented here. An overview of the diagnostic approach and staging of head and neck cancers is presented separately. (See "Overview of the diagnosis and staging of head and neck cancer".)

Malignancies arising in other organs within the head and neck regions are discussed in the relevant site-specific topics.


A multidisciplinary approach is required for optimal decision making, treatment planning, and posttreatment response assessment. This should include surgeons, medical oncologists, and radiation oncologists, as well as dentists, speech/swallowing pathologists, dieticians, and rehabilitation therapists. Specifically, a multidisciplinary tumor board affects diagnostic and treatment decisions in a significant number of patients with newly diagnosed head and neck tumors [1].

Furthermore, complex cases of head and neck cancer should be treated at high-volume centers whenever possible, where expertise in each of these disciplines may be better [2,3]. An analysis of outcomes from a large randomized trial (Radiation Therapy Oncology Group [RTOG] 0129) found that patients treated at centers with historically high accrual to head and neck clinical trials had a significantly better five-year overall survival rate compared with those treated at centers with historically low accrual (69 versus 51 percent) [4]. These differences could not be explained based upon differences in the prognostic factors of enrolled patients [1,3,5].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 12, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg 2010; 143:650.
  2. Corry J, Peters LJ, Rischin D. Impact of center size and experience on outcomes in head and neck cancer. J Clin Oncol 2015; 33:138.
  3. Boero IJ, Paravati AJ, Xu B, et al. Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol 2016; 34:684.
  4. Wuthrick EJ, Zhang Q, Machtay M, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 2015; 33:156.
  5. Tribius S, Donner J, Pazdyka H, et al. Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. Head Neck 2016; 38:1058.
  6. American Joint Committee on Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.
  7. Furness S, Glenny AM, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2010; :CD006386.
  8. Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4.
  9. O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016; 17:440.